Target intelligence / Profile preview

Bacterial DNA-directed RNA polymerase (RNAP)

Target
RNAP
Molecular classification
Enzyme, Transferase, Nucleotidyltransferase, Multi-subunit protein complex
01

Overview

Bacterial DNA-directed RNA polymerase (RNAP) is the essential multi-subunit enzyme complex responsible for transcribing genetic information from DNA into various forms of RNA, including mRNA, tRNA, and rRNA. The core enzyme typically consists of five subunits (α2ββ'ω), which associate with a sigma (σ) factor to form the holoenzyme capable of promoter-specific initiation (UniProt, P0A8V2). This machinery is a critical target for antimicrobial therapy because its structure and mechanism differ significantly from eukaryotic RNA polymerases, allowing for selective toxicity against bacterial pathogens. Drugs such as the rifamycin class (e.g., rifampin) bind to the β-subunit within the DNA-RNA channel to physically obstruct the growth of the RNA transcript, while others like fidaxomicin target the switch region to inhibit the initial steps of transcription (PubMed, PMID: 22230521). This target is clinically vital for treating infections such as tuberculosis and Clostridioides difficile, though its therapeutic utility is often challenged by the emergence of resistance through point mutations in the rpoB gene (StatPearls, NBK557485).

Other names
Bacterial RNA polymeraseDNA-dependent RNA polymeraseTranscription machineryRNAP complexBacterial RNA synthesis machinery
02

Mechanism of action

Inhibition of bacterial DNA-directed RNA polymerase by binding to the beta subunit (rifamycins) or the switch region (fidaxomicin), thereby sterically blocking the elongation of the nascent RNA chain or preventing the transition from transcription initiation to elongation (StatPearls, PMID: 30020613; PubMed, PMID: 21306243).

03

Biological functions

TranscriptionRNA synthesisGene expression regulationDNA binding
04

Disease associations

Bacterial infectionTuberculosisLeprosyClostridioides difficile-associated diarrheaTraveler's diarrhea
05

Safety considerations

HepatotoxicityPotent induction of cytochrome P450 enzymes (e.g., CYP3A4) leading to drug-drug interactionsRapid development of antimicrobial resistance via rpoB mutationsOrange-red discoloration of body fluids (rifamycins)Gastrointestinal distress
06

Interacting drugs

Rifampin

4 more in the full profile.

07

Biomarkers

rpoB gene mutationsMinimum Inhibitory Concentration (MIC)Sputum smear/culture conversionC. difficile toxin assay

Beyond the preview

Go deeper on Bacterial DNA-directed RNA polymerase (RNAP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial DNA-directed RNA polymerase (RNAP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call